2-phenyl-4-methylthiazole compounds and preparation method and application thereof
By introducing phenyl and aminoguanidine on 2-methyl-4-isothiazoline-3-one, synthesis of 2-phenyl-4-methylthiazole compounds, the existing bacterial resistance problem was solved and achieved The significant antibacterial activity against Staphylococcus aureus, E. coli and Pseudomonas aeruginosa provides new antibacterial candidate compounds.
Patent Information
- Application Number
- CN202310710414.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-06-15
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2043-06-15
AI Technical Summary
Due to the long-term use of existing fungicides, the increase in microbial resistance is difficult to effectively fight bacteria such as Staphylococcus aureus, E. coli and Pseudomonas aeruginosa, and lacks a new structure of fungicides.
By introducing lipophilic phenyl side chains and hydrophilic aminoguanidines on the basis of 2-methyl-4-isothiazoline-3-one, a series of new structures of 2-phenyl-4-methyl were designed and synthesized. The compound is obtained by the Hantzsch thiazole synthesis reaction and other corresponding reactions, and is used to prepare antibacterial agents.
This compound has significant antibacterial activity against Staphylococcus aureus, E. coli and Pseudomonas aeruginosa, which is better than the traditional 2-methyl-4-isothiazoline-3-one, and has great application value in treating bacteria Infection and industrial microbial hazards.
Smart Images

Figure CN116730946B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of antibacterial drugs and relates to an antibacterial drug or an industrial bactericide, and specifically relates to a 2-phenyl-4-methylthiazole compound with a new structure and a preparation method and application thereof. Background Art
[0002] Bacterial infection is a common disease and a common source of material or product deterioration in industry. It poses a serious threat to human health and industrial production. Although there are several types of fungicides or agents available in medicine and industry, the long history of use of these agents has led to the self-survival ability of microorganisms, which has led to a certain degree of drug resistance. Discovering new targets and fungicides with completely new structures has become an important research topic in this field. 2-Methyl-4-isothiazolin-3-one (MIT) is a broad-spectrum, highly effective fungicide widely used in industry. Its structural characteristics are that it contains nitrogen and sulfur atoms in the five-membered compound and a ketone group on the ring. It is possible to produce fungicides with completely new structures by isomerization and derivatization to construct 2-phenyl-4-methylthiazole compounds with completely new structures. Summary of the invention
[0003] The first object of the present invention is to provide a 2-phenyl-4-methylthiazole compound or a salt thereof which has a novel structure and has significant antibacterial activity against Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa.
[0004] The structural formula of the 2-phenyl-4-methylthiazole compound is shown in formula (IV):
[0005]
[0006] Among them, R is selected from
[0007] Preferably, said R is selected from
[0008] The second object of the present invention is to provide a method for preparing the 2-phenyl-4-methylthiazole compound having the structural formula (IV) as shown above. The method uses 3-hydroxybenzylsulfamide and 3-chloroacetylacetone as raw materials, obtains the first step product (I) through Hantzsch thiazole synthesis reaction, reacts the first step product (I) with bromoalkane (II) to obtain the second step product (III), and reacts the second step product (III) with aminoguanidine hydrochloride to obtain the final product (IV). The synthesis reaction formula of the 3-hydroxybenzylsulfamide thiazole compound is:
[0009]
[0010] Among them, R is selected from
[0011] Preferably, said R is selected from
[0012] Further preferably, the method comprises the following steps: a first step: adding 3-hydroxybenzylsulfamide, 3-chloroacetylacetone and ethanol into a reactor, heating and stirring to react, to obtain the first step product (I); a second step: adding the first step product (I), bromoalkane (II), potassium carbonate and N,N-dimethylformamide into a reactor, heating and stirring to react, to obtain the second step product (III); a third step: adding the second step product (III), aminoguanidine hydrochloride, lithium chloride and ethanol into a reactor, heating and stirring to react, to obtain the above-mentioned 2-phenyl-4-methylthiazole compound having the structural formula shown in formula (IV).
[0013] The total yield of the preparation method of the present invention can be between 33% and 51%.
[0014] Preferably, the molar ratio of 3-hydroxybenzylsulfamide and 3-chloroacetylacetone in the first step is 1:1.2; the molar ratio of the first step product (I), bromoalkane (II) and potassium carbonate in the second step is 1:1:1.7; the molar ratio of the second step product (III), aminoguanidine hydrochloride and lithium chloride in the third step is 1:1.3:0.4; and the heating and stirring reaction is a stirring reaction at 70°C.
[0015] Preferably, the bromoalkane is selected from bromocyclohexane, bromocycloheptane or 1-bromo-n-heptane.
[0016] The third object of the present invention is to provide the use of the above-mentioned 2-phenyl-4-methylthiazole compound or its salt represented by the structural formula (IV) in the preparation of antibacterial agents.
[0017] Preferably, the antibacterial agent is an agent against Staphylococcus aureus, Escherichia coli and / or Pseudomonas aeruginosa.
[0018] The fourth object of the present invention is to provide an antibacterial agent, which contains the 2-phenyl-4-methylthiazole compound or its salt represented by the above structural formula (IV) as an active ingredient.
[0019] Compared with the prior art, the present invention has the following beneficial effects:
[0020] According to modern drug design theory and organic synthesis experimental technology, the present invention transforms 2-methyl-4-isothiazoline-3-one (MIT), introduces a lipophilic phenyl side chain at the C2 position of the thiazole ring and a hydrophilic aminoguanidine at the C5 position, designs and synthesizes a series of 2-phenyl-4-methylthiazole compounds with new structures, and conducts antibacterial activity research. The research results show that this type of novel 2-phenyl-4-methylthiazole compound has significant antibacterial activity against Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa, and has great application value in treating bacterial infection diseases or industrial microbial hazards. Some target compounds have significant antibacterial effects on Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa, which are better than the control agent 2-methyl-4-isothiazoline-3-one (MIT), and can be studied as antibacterial candidate compounds. DETAILED DESCRIPTION
[0021] The following examples are provided to further illustrate the present invention, rather than to limit the present invention.
[0022] Example 1
[0023] Preparation steps of 2-(3-(cyclohexyloxy)phenyl)-4-methyl-5-(1-(guanidinoimino)ethyl)-thiazole (IVa):
[0024]
[0025] 10 mmol of 3-hydroxybenzylsulfamide, 12 mmol of 3-chloroacetylacetone and 60 mL of ethanol were added to a 150 mL flask, and the mixture was stirred at 70° C. for 3 hours. After the reaction was completed, the mixture was filtered, and the residue was collected and air-dried to obtain the first step product I, i.e., 2-(3-hydroxyphenyl)-4-methyl-5-acetylthiazole, with a yield of 80%.
[0026] 5 mmol of the first step product I, 5 mmol of bromocyclohexane IIa, 8.5 mmol of potassium carbonate, and 15 mL of N,N-dimethylformamide were added to a 100 mL flask, and the mixture was stirred at 70°C for 12 hours. After the reaction was completed, the reaction mixture was poured onto crushed ice, filtered, and purified by silica gel column chromatography (300-400 mesh, eluent: ethyl acetate: hexane volume ratio of 3:7) to obtain the second step product IIIa, i.e. 2-(3-(cyclohexyloxy)phenyl)-4-methyl-5-acetylthiazole, with a yield of 70%.
[0027] 2 mmol of the second step product IIIa, 2.6 mmol of aminoguanidine hydrochloride, 0.8 mmol of lithium chloride and 50 mL of ethanol were added to a 100 mL flask, and the mixture was stirred at 70°C for 24 hours. After the reaction was completed, the mixture was dried under reduced pressure and purified by silica gel column chromatography (300-400 mesh, eluent: methanol: dichloromethane in a volume ratio of 1:5) to obtain the target product (IVa) with a yield of 80% and a total yield of 44%. 1 H NMR (400MHz, DMSO-d6, δ): 10.97 (s, 1H, guanidine), 7.84 (s, 3H, guanidine), 7.71 (d, J = 7.5Hz, 1 H,1-benzene),7.44(t,J=7.5Hz,1H,1-benzene),7.29(s,1H,1-benzene),7.04(d,J=7.5Hz,1H, 1-benzene),3.64(m,1H,cyclohexane),2.49(s,3H,methyl),2.38(s,3H,methyl),1.95(m,2H,cyclohexane),1.70(m,2H,cyclohexane),1.53(m,2H,cyclohexane),1.44(m,4H,cyclohexane). HRMS(ESI)m / z:[M+H] + Calculate for C 19 H 26 N5OS,372.1858; found372.1871.
[0028] Example 2
[0029] Preparation steps of 2-(3-(cycloheptyloxy)phenyl)-4-methyl-5-(1-(guanidinoimino)ethyl)-thiazole (IVb):
[0030]
[0031] 10 mmol of 3-hydroxybenzylsulfamide, 12 mmol of 3-chloroacetylacetone and 60 mL of ethanol were added to a 150 mL flask, and the mixture was stirred at 70° C. for 3 hours. After the reaction was completed, the mixture was filtered, and the residue was collected and air-dried to obtain the first step product I, i.e., 2-(3-hydroxyphenyl)-4-methyl-5-acetylthiazole, with a yield of 80%.
[0032] 5 mmol of the first step product I, 5 mmol of bromocycloheptane IIb, 8.5 mmol of potassium carbonate, and 15 mL of N,N-dimethylformamide were added to a 100 mL flask, and the mixture was stirred at 70°C for 12 hours. After the reaction was completed, the reaction mixture was poured onto crushed ice, filtered, and purified by silica gel column chromatography (300-400 mesh, eluent: ethyl acetate: hexane volume ratio of 3:7) to obtain the second step product IIIb, i.e. 2-(3-(cycloheptyloxy)phenyl)-4-methyl-5-acetylthiazole, with a yield of 80%.
[0033] 2 mmol of the second step product IIIb, 2.6 mmol of aminoguanidine hydrochloride, 0.8 mmol of lithium chloride and 50 mL of ethanol were added to a 100 mL flask, and the mixture was stirred at 70° C. for 24 hours. After the reaction was completed, the mixture was dried under reduced pressure and purified by silica gel column chromatography (300-400 mesh, eluent: methanol: dichloromethane in a volume ratio of 1:5) to obtain the target product (IVb) with a yield of 80% and a total yield of 51%. 1 H NMR (400MHz, DMSO-d6, δ): 10.97 (s, 1H, guanidine), 7.84 (s, 3H, guanidine), 7.71 (d, J = 7.5Hz, 1H, 1-benzene), 7.44 (t, J = 7.5Hz, 1H, 1-benzene), 7.29 (s, 1H, 1-benzene) ene), 7.04 (d, J = 7.5Hz, 1H, 1-benzene), 3.50 (m, 1H, cyclohexane), 2.49 (s, 3H, methyl), 2.38 (s, 3H, methyl), 1.75 (m, 2H, cyclohexane), 1.56 (m, 10H, cyclohexane). HRMS(ESI)m / z:[M+H] + Calculate for C 20 H 28 N5OS,386.2014; found 386.2034.
[0034] Example 3
[0035] Preparation steps of 2-(3-(n-heptyloxy)phenyl)-4-methyl-5-(1-(guanidinoimino)ethyl)-thiazole (IVc):
[0036]
[0037] 10 mmol of 3-hydroxybenzylsulfamide, 12 mmol of 3-chloroacetylacetone and 60 mL of ethanol were added to a 150 mL flask, and the mixture was stirred at 70° C. for 3 hours. After the reaction was completed, the mixture was filtered, and the residue was collected and air-dried to obtain the first step product I, i.e., 2-(3-hydroxyphenyl)-4-methyl-5-acetylthiazole, with a yield of 80%.
[0038] 5 mmol of the first step product I, 5 mmol of 1-bromo-n-heptane IIc, 8.5 mmol of potassium carbonate, and 15 mL of N,N-dimethylformamide were added to a 100 mL flask, and the mixture was stirred at 70° C. for 12 hours. After the reaction was completed, the reaction mixture was poured onto crushed ice, filtered, and purified by silica gel column chromatography (300-400 mesh, eluent: ethyl acetate: hexane volume ratio of 3:7) to obtain the second step product IIIc, i.e. 2-(3-(n-heptyloxy)phenyl)-4-methyl-5-acetylthiazole, with a yield of 60%.
[0039] 2 mmol of the second step product IIIc, 2.6 mmol of aminoguanidine hydrochloride, 0.8 mmol of lithium chloride and 50 mL of ethanol were added to a 100 mL flask, and the mixture was stirred at 70°C for 24 hours. After the reaction was completed, the mixture was dried under reduced pressure and purified by silica gel column chromatography (300-400 mesh, eluent: methanol: dichloromethane in a volume ratio of 1:5) to obtain the target product (IVc) with a yield of 70% and a total yield of 33%. 1 H NMR (400MHz, DMSO-d6, δ): 10.97 (s, 1H, guanidine), 7.84 (s, 3H, guanidine), 7.71 (d, J = 7.5Hz ,1H,1-benzene),7.44(t,J=7.5Hz,1H,1-benzene),7.29(s,1H,1-benzene),7.04(d,J=7.5Hz, 1H,1-benzene),4.06(t,J=7.0Hz,2H,methylene),2.49(s,3H,methyl),2.38(s,3H,methyl),1.74(m,2H,methylene),1.42(m,2H,methylene),1.26(m,6H,methylene),0.88(m,3H,methyl). HRMS(ESI)m / z:[M+H] + Calculate for C 20 H 30 N5OS,388.2171; found 388.2193.
[0040] Example 4
[0041] Preparation steps of 2-(3-(p-methylbenzyloxy)phenyl)-4-methyl-5-(1-(guanidinoimino)ethyl)-thiazole (IVd):
[0042]
[0043] 10 mmol of 3-hydroxybenzylsulfamide, 12 mmol of 3-chloroacetylacetone and 60 mL of ethanol were added to a 150 mL flask, and the mixture was stirred at 70° C. for 3 hours. After the reaction was completed, the mixture was filtered, and the residue was collected and air-dried to obtain the first step product I, i.e., 2-(3-hydroxyphenyl)-4-methyl-5-acetylthiazole, with a yield of 80%.
[0044] 5 mmol of the first step product I, 5 mmol of 4-methylbenzyl bromide IId, 8.5 mmol of potassium carbonate, and 15 mL of N,N-dimethylformamide were added to a 100 mL flask, and the mixture was stirred at 70° C. for 12 hours. After the reaction was completed, the reaction mixture was poured onto crushed ice, filtered, and purified by silica gel column chromatography (300-400 mesh, eluent: ethyl acetate: hexane volume ratio of 3:7) to obtain the second step product IIId, i.e. 2-(3-(p-methylbenzyloxy)phenyl)-4-methyl-5-acetylthiazole, with a yield of 80%.
[0045] 2 mmol of the second step product IIId, 2.6 mmol of aminoguanidine hydrochloride, 0.8 mmol of lithium chloride and 50 mL of ethanol were added to a 100 mL flask, and the mixture was stirred at 70° C. for 24 hours. After the reaction was completed, the mixture was dried under reduced pressure and purified by silica gel column chromatography (300-400 mesh, eluent: methanol: dichloromethane in a volume ratio of 1:5) to obtain the target product (IVd) with a yield of 80% and a total yield of 51%. 1 H NMR (400MHz, DMSO-d6, δ): 10.97 (s, 1H, guanidine), 7.84 (s, 3H, guanidine), 7.71 (d, J = 7.5Hz, 1H, 1-benzene), 7.44 (t, J = 7.5Hz, 1H, 1-benzene) e),7.29(s,1H,1-benzene),7.13(m,5H,1-benzene),5.09(s,2H,methylene),2.49(s,3H,methyl),2.38(s,3H,methyl),2.19(s,3H,methyl). HRMS(ESI)m / z:[M+H] + Calculate for C 21 H 24 N5OS,394.1701; found 394.1713.
[0046] Example 5
[0047] Antimicrobial activity test of target compounds:
[0048] The antibacterial activity of the target compound (2-phenyl-4-methylthiazole compound prepared in Example 1-4) against Staphylococcus aureus (Staphylococcus aureus ATCC 6538P), Escherichia coli (Escherichia coli ATCC 8739), and Pseudomonas aeruginosa (Pseudomonas aeruginosa ATCC 9027) was determined by using 2-methyl-4-isothiazolin-3-one (MIT) as a control agent and the MIC of the target compound was determined by the microdilution method.
[0049] The experimental steps of microdilution method are as follows:
[0050] Add 200 μL of the sample (2-methyl-4-isothiazoline-3-one and the 2-phenyl-4-methylthiazole compound prepared in Examples 1-4) with a concentration of 256 μg / mL to the first column of the 96-well plate, add 100 μL of MH broth to columns 2-12 respectively, then take 100 μL from column 1 and add it to column 2 to mix, then take 100 μL from column 2 and add it to column 3 to mix, and so on, finally take 100 μL from column 10 and add it to column 11 to mix, then take out 100 μL of excess liquid and discard. Take 100 μL of 10 6 cfu / mL of bacterial solution was added to each well in columns 1-11, and 100 μL of the concentration of 10 6 cfu / mL of bacterial solution was added to the first four wells of the 12th column, and 100μL of MH broth was added to the last four wells of the 12th column. The final volume of each well was 200μL. The concentrations of the samples to be tested in columns 1-11 were 128, 64, 32, 16, 8, 4, 2, 1, 0.5, 0.25, and 0.12μg / mL, respectively. The first four wells of the 12th column were bacteria-free and drug-free (positive growth control), and the last four wells of the 12th column were bacteria-free and drug-free (sterile control). Three replicates were made for each sample to be tested. After the 96-well plate was incubated in a 37°C oven for 24 hours, the OD was measured using an enzyme reader. 600 Value, OD 600 The concentration of the wells with values close to the sterile control is the minimum inhibitory concentration (MIC).
[0051] The results show:
[0052] (1) The MICs of 2-methyl-4-isothiazolin-3-one (MIT) against Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa were 16 μg / mL, 16 μg / mL, and 16 μg / mL, respectively.
[0053] (2) The MICs of 2-(3-(cyclohexyloxy)phenyl)-4-methyl-5-(1-(guanidinoimino)ethyl)-thiazole (IVa) against Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa were 1 μg / mL, 2 μg / mL, and 4 μg / mL, respectively. Its antibacterial effect against Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa was better than that of the control agent 2-methyl-4-isothiazoline-3-one (MIT).
[0054] (3) The MICs of 2-(3-(cycloheptyloxy)phenyl)-4-methyl-5-(1-(guanidinoimino)ethyl)-thiazole (IVb) against Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa were 1 μg / mL, 1 μg / mL, and 2 μg / mL, respectively. The antibacterial effect of 2-(3-(cycloheptyloxy)phenyl)-4-methyl-5-(1-(guanidinoimino)ethyl)-thiazole (IVb) against Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa was better than that of the control agent 2-methyl-4-isothiazoline-3-one (MIT).
[0055] (4) The MICs of 2-(3-(n-heptyloxy)phenyl)-4-methyl-5-(1-(guanidinoimino)ethyl)-thiazole (IVc) against Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa were 2 μg / mL, 4 μg / mL, and 4 μg / mL, respectively. The antibacterial effect of 2-(3-(n-heptyloxy)phenyl)-4-methyl-5-(1-(guanidinoimino)ethyl)-thiazole (IVc) against Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa was better than that of the control agent 2-methyl-4-isothiazoline-3-one (MIT).
[0056] (5) The MICs of 2-(3-(p-methylbenzyloxy)phenyl)-4-methyl-5-(1-(guanidinoimino)ethyl)-thiazole (IVd) against Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa were 8 μg / mL, 8 μg / mL, and 16 μg / mL, respectively. Its antibacterial effects against Staphylococcus aureus and Escherichia coli were better than those of the control agent 2-methyl-4-isothiazolin-3-one (MIT), while its antibacterial effect against Pseudomonas aeruginosa was comparable to that of the control agent 2-methyl-4-isothiazolin-3-one (MIT).
[0057] The above are only preferred embodiments of the present invention. It should be noted that the above preferred embodiments should not be regarded as limiting the present invention, and the protection scope of the present invention should be based on the scope defined by the claims. For ordinary technicians in this technical field, several improvements and modifications can be made without departing from the spirit and scope of the present invention, and these improvements and modifications should also be regarded as the protection scope of the present invention.
Claims
1. 2-phenyl-4-methylthiazole compounds or their salts, wherein the structural formula of the 2-phenyl-4-methylthiazole compounds is as shown in formula (IV): The R is selected from 2. The 2-phenyl-4-methylthiazole compound according to claim 1, characterized in that: The R is selected from 3. A method for preparing the 2-phenyl-4-methylthiazole compound according to claim 1, characterized in that: 3-Hydroxybenzylsulfamide and 3-chloroacetylacetone are used as raw materials, and a first step product (I) is obtained by a Hantzsch thiazole synthesis reaction. The first step product (I) reacts with an alkyl bromide (II) to obtain a second step product (III). The second step product (III) reacts with aminoguanidine hydrochloride via a Schiff base to obtain a final product, a 2-phenyl-4-methylthiazole compound (IV). The synthesis reaction formula of the 2-phenyl-4-methylthiazole compound is: Wherein, the R is selected from 4. The method for preparing 2-phenyl-4-methylthiazole compounds according to claim 3, characterized in that: The R is selected from 5. The preparation method according to claim 3, characterized in that: The following steps are involved: The first step is to add 3-hydroxybenzylsulfamide, 3-chloroacetylacetone and ethanol into a reactor, heat and stir to react, and obtain the first step product (I); the second step is to add the first step product (I), bromoalkane (II), potassium carbonate and N,N-dimethylformamide into a reactor, heat and stir to react, and obtain the second step product (III); the third step is to add the second step product (III), aminoguanidine hydrochloride, lithium chloride and ethanol into a reactor, heat and stir to react, and obtain a 2-phenyl-4-methylthiazole compound.
6. The preparation method according to claim 5, characterized in that: The molar ratio of 3-hydroxybenzylsulfamide and 3-chloroacetylacetone in the first step is 1:1.2; the molar ratio of the first step product (I), bromoalkane (II) and potassium carbonate in the second step is 1:1:1.7; the molar ratio of the second step product (III), aminoguanidine hydrochloride and lithium chloride in the third step is 1:1.3:0.4; the heating and stirring reaction is a stirring reaction at 70°C.
7. Use of the 2-phenyl-4-methylthiazole compound or its salt according to claim 1 in the preparation of an antibacterial agent.
8. The use according to claim 7, characterized in that: The antibacterial agent is an agent against Staphylococcus aureus, Escherichia coli and / or Pseudomonas aeruginosa.
9. An antibacterial agent, characterized in that Contains the 2-phenyl-4-methylthiazole compound or its salt according to claim 1 as an active ingredient.
10. The antibacterial agent according to claim 9, characterized in that The antibacterial agent is an agent against Staphylococcus aureus, Escherichia coli and / or Pseudomonas aeruginosa.
